Annual Medicare spending could increase by $2 to $5 billion if Medicare expands coverage for dementia drug lecanemab

The anti-dementia medication lecanemab and its ancillary costs could add $2 billion to $5 billion in annual Medicare spending if the Centers for Medicare and Medicaid Services (CMS) revise their coverage decision. Currently, the medication is covered only for patients who are enrolled in clinical trials.